| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02438007 Details | 2023-03-15 Interventional | 3 | 953 | 3-hydroxy-17-(1… Prostatic Neopl… Prostate Cancer | - - | |||
| NCT01709734 Details | 2023-03-15 Interventional | 2 | 126 | 3-hydroxy-17-(1… Prostatic Neopl… Prostate Cancer | Study was terminated prematurely in all investigational study centers upon recommendation from
the study's Data Monitoring Committee (DMC).
Study was stopped due to lack of efficacy. - | |||
| NCT05065164 Details | 2023-03-14 Interventional | 2/3 | 0 | Denosumab Denosumab Aller… | no partcipants enrolled - | |||
| NCT04854512 Details | 2023-03-14 Interventional | 3 | - | Metformin Diabetes Mellit… Diabetes Mellit… | Strategic company decision - not related to a safety concern - | |||
| NCT03030131 Details | 2023-03-14 Interventional | 2 | 50 | Durvalumab Carcinoma, Non-… Lung Neoplasms | Definitive discontinuation according to safety monitoring of death from the 46th patient
onwards. - | |||
| NCT04954196 Details | 2023-03-13 Interventional | 2 | 0 | Amlodipine Frozen Embryo T… | No participants enrolled - | |||
| NCT04521335 Details | 2023-03-13 Interventional | 1 | 2 | Copper Disulfiram Multiple Myelom… Neoplasms, Plas… | Closed at PI's Request - | |||
| NCT04002011 Details | 2023-03-13 Interventional | 2 | 0 | Apixaban Dabigatran Edoxaban Rivaroxaban Warfarin Anticoagulant-i… | Submission process abandoned. No patient enrolled. - | |||
| NCT03439033 Details | 2023-03-13 Interventional | 2 | 273 | Edetic Acid N,N'-bis(2-hydr… Prostatic Neopl… Prostate Cancer | Study Drug was FDA approved Summer 2021 One limitation is the small number of cases available for specificity analysis resulting in a negligible sample size of patients who had a true negative reference. Another limitation is multiple patients sought care at other institutions. As a result, information was not complete for several patients. Only a small number of the subjects had 2-year follow-up or underwent confirmatory biopsy, which introduces the possibility of selection bias. | |||
| NCT02423265 Details | 2023-03-13 Interventional | 4 | 0 | Ranolazine Angina, Stable Arteriosclerosi… Coronary Artery… Ischemia Myocardial Isch… Chronic Stable … | slow recruitment; local new issues with CMR after study start - | |||
| NCT04203498 2019-002623-14 Details | 2023-03-10 Interventional | 3 | 238 | Nabiximols Multiple Sclero… Muscle Spastici… Sclerosis Multiple Sclero… | This study was terminated based on a business decision by the Sponsor. - | |||
| NCT03878927 Details | 2023-03-10 Interventional | 1 | 11 | Gemtuzumab Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myeloid L… | Dose limiting toxicities. - | |||
| NCT03639610 2018-000478-31 Details | 2023-03-10 Interventional | 2 | 35 | Dexamethasone Melphalan Multiple Myelom… Neoplasms, Plas… Renal Insuffici… Renal Impairmen… | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. Between-group comparisons were not performed in this study due the small number of patients in each cohort, as well as differences with regards to some baseline characteristics. | |||
| NCT00543127 2007-003417-14 Details | 2023-03-10 Interventional | 3 | [1 Refs] | 870 | Anastrozole Fulvestrant Breast Neoplasm… Breast Cancer | Unjustified decision of company that funded the trial. - | ||
| NCT04946435 Details | 2023-03-09 Interventional | 1 | 0 | Anti-Bacterial … Intracranial Pa… | We are no longer going to undertake the study. - | |||
| NCT04784559 2020-005951-19 Details | 2023-03-09 Interventional | 3 | 205 | Dexamethasone Favipiravir Remdesivir COVID-19 Communicable Di… Infections COVID-19 Infect… | Sponsor has decided to end the study prematurely based on significant difficulties in the
recruitment of patients, despite the implementation of corrective measures that still failed to
increase the accrual rate required for a feasible completion. - | |||
| NCT04412707 Details | 2023-03-09 Interventional | 2 | 27 | Dexamethasone Melphalan RRMM | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. - | |||
| NCT04277663 Details | 2023-03-09 Interventional | 3 | 136 | Interferons Melanoma Acral Melanoma … | Due to the company's development strategy adjustment ，Innovent Bioligics decided not to
continue the study after consultation with investigators - | |||
| NCT04156659 Details | 2023-03-09 Interventional | 2 | 0 | Tisagenlecleuce… Leukemia Leukemia, Lymph… Precursor Cell … B-cell Acute Ly… | This study was cancelled before enrolling any patients for business related reasons. - | |||
| NCT03948178 Details | 2023-03-09 Interventional | 3 | 227 | Simendan Amyotrophic Lat… Motor Neuron Di… Sclerosis | This was an open label extension for patients completing the REFALS study (3119002;
NCT03505021). Study 3119002 showed lack of efficacy of ODM109 so the sponsor decided to
terminate this study - |